Am J Pathol
- ALBANESE C, Rodriguez OC 
 From The American Journal of Pathology's Archives: Pioneering Studies on the 
Mechanisms of Metastatic Prostate Cancer.
 Am J Pathol. 2025;195:1756-1757.
 
 
 Anticancer Res
 
 
- YUMISAKI H, Kubo N, Oike T, Kawamura H, et al 
 A Dosimetric Evaluation of the Feasibility and Robustness of 
Ultra-hypofractionated Carbon Ion Radiotherapy Planning for the Treatment of 
Prostate Cancer.
 Anticancer Res. 2025;45:4453-4464.
 
 
- IMAFUKU H, Terashima K, Fukunishi K, Suefuji H, et al 
 Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients.
 Anticancer Res. 2025;45:4465-4472.
 
 
- LEHRER S, Rheinstein PH 
 PROX1 Expression Is Significantly Associated With ERG Expression and the 
TMPRSS2-ERG Fusion Gene in Prostate Cancer.
 Anticancer Res. 2025;45:4381-4388.
 
 
 BJU Int
 
 
- BONADDIO J, Carll J, Eapen R, Sathianathen N, et al 
 The role of PSMA PET/CT in staging patients with intermediate-risk prostate 
cancer.
 BJU Int. 2025 Sep 30. doi: 10.1111/bju.70015.
 
 
- SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al 
 Re: 'Real-world use of androgen-deprivation therapy intensification for 
metastatic hormone-sensitive prostate cancer: a systematic review'.
 BJU Int. 2025 Oct 3. doi: 10.1111/bju.70024.
 
 
 BMC Cancer
 
 
- SEVEN D, Dalan AB, Bayrak OF 
 Targeting GSTM3 for therapeutic potential in advanced prostate cancer.
 BMC Cancer. 2025;25:1493.
 
 
- JIN L, Ma Z, Gao F, Li M, et al 
 Automated machine learning for prostate cancer detection and Gleason score 
prediction using T2WI: a diagnostic multi-center study.
 BMC Cancer. 2025;25:1483.
 
 
- KIM JK, Park MU, Lee D, Kim HJ, et al 
 Sustained PSA screening is associated with downstaging and improved survival in 
prostate cancer: a 12-year Korean cohort study.
 BMC Cancer. 2025;25:1462.
 
 
- JIN Y, Zhang Y, Wang M, Bai X, et al 
 Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto((R))) in advanced 
prostate cancer: a disproportionality analysis based on the fda's adverse event 
reporting system (FAERS).
 BMC Cancer. 2025;25:1470.
 
 
 BMC Urol
 
 
- LI Y, Pan D, Wang Z, Ji J, et al 
 The diagnostic value of urinary exosomes in prostate cancer: a prospective 
multicenter study.
 BMC Urol. 2025;25:246.
 
 
- IKEDA M, Uemura K, Ito Y, Ito H, et al 
 Comparative real-world study of apalutamide and darolutamide in Japanese patients 
with non-metastatic castration-resistant prostate cancer.
 BMC Urol. 2025;25:235.
 
 
 Cancer Imaging
 
 
- MIN K, Lin Q, Qiu D 
 Precision medicine in prostate cancer: individualized treatment through 
radiomics, genomics, and biomarkers.
 Cancer Imaging. 2025;25:116.
 
 
 Cancer Lett
 
 
- AHMAD G, El Sadda R, Botchkina G, Ojima I, et al 
 Corrigendum to "Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 Inhibits 
prostate cancer stem cell-induced tumor growth" [Cancer Lett. 2017 Aug 
11;406:71-80].
 Cancer Lett. 2025 Sep 23:218043. doi: 10.1016/j.canlet.2025.218043.
 
 
 Cancer Res
 
 
- ALHOURANI F, Tauziet M, Ayeul M, Dambrun P, et al 
 Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in 
Prostate Cancer.
 Cancer Res. 2025 Oct 1. doi: 10.1158/0008-5472.CAN-24-3974.
 
 
 Eur Urol
 
 
- LIU H, Sun F, Wu J 
 Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible 
Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk 
Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. 
https://doi.org/10.1016/j.e
 Eur Urol. 2025 Sep 27:S0302-2838(25)04691-3. doi: 10.1016/j.eururo.2025.
 
 
- STABILE A, Montorsi F 
 Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible 
Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk 
Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. 
https://doi.org/10.1016/j.e
 Eur Urol. 2025 Sep 23:S0302-2838(25)04641-X. doi: 10.1016/j.eururo.2025.09.4128.
 
 
- GINSBURG KB, Zamani A, Borza T 
 Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. 
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate 
Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In 
press. https:/
 Eur Urol. 2025 Sep 24:S0302-2838(25)04647-0. doi: 10.1016/j.eururo.2025.
 
 
- PALMSTEDT E, Hugosson J, Arnsrud Godtman R 
 Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor 
re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. 
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate 
Cancer: Extende
 Eur Urol. 2025 Sep 24:S0302-2838(25)04644-5. doi: 10.1016/j.eururo.2025.09.4130.
 
 
- CONTEDUCA V, Bruno G, Landriscina M 
 Reconciling Clinical and Molecular Heterogeneity in Metastatic 
Castration-resistant Prostate Cancer: The Promise of Integrated Prognostic 
Models.
 Eur Urol. 2025 Sep 27:S0302-2838(25)04676-7. doi: 10.1016/j.eururo.2025.09.4140.
 
 
- ARTAMONOVA N, Heidegger I 
 Re: Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary 
Patterns in Prostate Cancer Prevention and Management: A Systematic Review of 
Prospective Cohort Studies and Randomized Clinical Trials. Eur Urol. In press. 
https://doi.org/10.1
 Eur Urol. 2025 Sep 27:S0302-2838(25)04697-4. doi: 10.1016/j.eururo.2025.09.4147.
 
 
- WANG Y, Lu Q, Zhao X 
 Re: Lars Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of 
Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and 
Watchful Waiting in Early Prostate Cancer. Eur Urol. In press. 
https://doi.org/10.1016/j.eururo.2
 Eur Urol. 2025 Sep 27:S0302-2838(25)04696-2. doi: 10.1016/j.eururo.2025.
 
 
- BERNARDINO RM, van der Kwast T, Fleshner NE 
 Reply to Nour Khalil, Guiseppe Maiolino, and Eric Barret's Letter to the Editor 
re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal 
Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging 
Perspectives. Eu
 Eur Urol. 2025 Sep 27:S0302-2838(25)04689-5. doi: 10.1016/j.eururo.2025.09.4146.
 
 
- STRAUSS AS, Cleves A, Dahm P 
 Re: Elio Mazzone, Alice Thomson, David C. Chen, et al. The Role of 
Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of 
Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence 
of Prostate Cancer Aft
 Eur Urol. 2025 Sep 26:S0302-2838(25)04651-2. doi: 10.1016/j.eururo.2025.09.4131.
 
 
- MONTORSI F, Zaurito P, Gandaglia G 
 Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance 
Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results 
from a Large Cohort Study. Eur Urol 2025;88:167-75.
 Eur Urol. 2025 Sep 26:S0302-2838(25)04685-8. doi: 10.1016/j.eururo.2025.
 
 
- FISHER DJ, Burdett S, Vale CL 
 Reply to Shenglong Li and Cuicui Wang's Letter to the Editor re: Sarah Burdett, 
David J. Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with 
Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A 
Collaborative Sy
 Eur Urol. 2025 Sep 25:S0302-2838(25)04653-6. doi: 10.1016/j.eururo.2025.
 
 
- MONTIRONI R, Cimadamore A, Lopez-Beltran A, Cheng L, et al 
 Re: Lucia L. Rijstenberg, Hridya Harikumara, Esther I. Verhoef, et al. 
Identification of Intraductal-to-Invasive Spatial Transitions in Prostate Cancer: 
Proposal for a New Unifying Model on Intraductal Carcinogenesis. Histopathology 
2025;86:1091-100.
 Eur Urol. 2025 Sep 25:S0302-2838(25)04656-1. doi: 10.1016/j.eururo.2025.
 
 
- MISZCZYK M, Sanchez-Salas R, Emberton M, Shariat SF, et al 
 Re: Karolina Menne Guricova, Cedric Draulans, Floris J. Pos, et al. Focal Boost 
to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with 
Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial. J Clin Oncol. In 
press. https:/
 Eur Urol. 2025 Sep 24:S0302-2838(25)04650-0. doi: 10.1016/j.eururo.2025.09.4133.
 
 
 Int J Radiat Oncol Biol Phys
 
 
- COOPER S, Westley RL, Biscombe K, Dunlop A, et al 
 HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance 
Imaging-Guided Adaptive Prostate Radiation Therapy.
 Int J Radiat Oncol Biol Phys. 2025;123:773-782.
 
 
- YAZDANI E, Sadeghi M, Karamzade-Ziarati N, Jabari P, et al 
 Machine Learning-based Dose Prediction in [(177)Lu]Lu-PSMA-617 Therapy by 
Integrating Biomarkers and Radiomic Features from [(68)Ga]Ga-PSMA-11 Positron 
Emission Tomography/Computed Tomography.
 Int J Radiat Oncol Biol Phys. 2025;123:891-908.
 
 
- LUDDY KA, West J, Robertson-Tessi M, Desai B, et al 
 Evolutionary double-bind treatment using radiotherapy and NK cell-based 
immunotherapy in prostate cancer.
 Int J Radiat Oncol Biol Phys. 2025 Sep 23:S0360-3016(25)06293.
 
 
- YU JB, DeStephano DM, Jeffers B, Tward AE, et al 
 The Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer.
 Int J Radiat Oncol Biol Phys. 2025 Sep 23:S0360-3016(25)06282.
 
 
- ONAL C, Guler OC, Torun N, Demirhan B, et al 
 Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission 
Tomography/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer 
After Definitive Radiation Therapy: Prognostic Implications.
 Int J Radiat Oncol Biol Phys. 2025 Jul 17:S0360-3016(25)04496.
 
 
 Int J Urol
 
 
- SUZUKI K, Khan N, Taguchi T, Hattori K, et al 
 Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant 
Prostate Cancer in Japan: The ARASHI Study.
 Int J Urol. 2025 Oct 3. doi: 10.1111/iju.70235.
 
 
- SASAKI T, Higashi S, Nishikawa T, Sugino Y, et al 
 Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With 
Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A 
Preliminary Prospective Study.
 Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70251.
 
 
- YASUDA Y, Yoshida S, Matsubara D, Takahara T, et al 
 Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for 
Patients With Oligometastatic Castration-Resistant Prostate Cancer.
 Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70253.
 
 
- DENIZ ME, Gur G, Kayra MV, Hasbay B, et al 
 PSMA PET/CT and Multiparametric MRI in Assessing Local Extension and Lymph Node 
Metastasis in Prostate Cancer.
 Int J Urol. 2025 Sep 24. doi: 10.1111/iju.70239.
 
 
 J Clin Oncol
 
 
- LI J, Huang R, Hu H 
 Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: 
RAVENS Trial Insights.
 J Clin Oncol. 2025 Oct 3:JCO2501476. doi: 10.1200/JCO-25-01476.
 
 
- TRAN PT, Wang JH, Tang C, Kiess AP, et al 
 Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate 
Cancer: RAVENS Trial Insights.
 J Clin Oncol. 2025 Oct 3:JCO2501855. doi: 10.1200/JCO-25-01855.
 
 
 J Nucl Med
 
 
- HOYVIK AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, et al 
 Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in 
PSMA-Positive Subcutaneous Prostate Cancer Xenografts.
 J Nucl Med. 2025 Oct 3:jnumed.125.270444. doi: 10.2967/jnumed.125.270444.
 
 
-  
 Biomarkers in Prostate Cancer: What's in the Blood?
 J Nucl Med. 2025;66:6A.
 
 
- LIU F, Monterosso ME, Boucher D, Shakti S, et al 
 Preclinical Evaluation of [(212)Pb]Pb-ADVC001: A Prostate-Specific Membrane 
Antigen-Targeted alpha-Therapy for Prostate Cancer.
 J Nucl Med. 2025 Sep 25:jnumed.125.269707. doi: 10.2967/jnumed.125.269707.
 
 
- HADASCHIK B, Gillessen S, Sartor O 
 (177)Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for 
Metastatic Hormone-Sensitive Prostate Cancer.
 J Nucl Med. 2025 Sep 25:jnumed.125.270836. doi: 10.2967/jnumed.125.270836.
 
 
- GIRI VK, Kolodny GM, Garnick MB 
 First-Line [(177)Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local 
Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
 J Nucl Med. 2025 Sep 25:jnumed.125.270704. doi: 10.2967/jnumed.125.270704.
 
 
- PEPIN A, Doucette A, Vapiwala N, Narayan VK, et al 
 Safety of the Combination of External Beam Radiotherapy with (177)Lu-PSMA-617 in 
Patients with Metastatic Castration-Resistant Prostate Cancer.
 J Nucl Med. 2025 Sep 25:jnumed.125.270316. doi: 10.2967/jnumed.125.270316.
 
 
- ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al 
 Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
 J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
 
 
- TEUNISSEN FR, Oprea-Lager DE, Peters SMB, Smeenk RJ, et al 
 Current Developments in Combining External-Beam Radiotherapy and (177)Lu-Labeled 
PSMA Ligands for Prostate Cancer Treatment.
 J Nucl Med. 2025 Oct 3:jnumed.125.270465. doi: 10.2967/jnumed.125.270465.
 
 
- SARTOR O, Emmett L, Herrmann K 
 Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer.
 J Nucl Med. 2025 Oct 3:jnumed.125.271144. doi: 10.2967/jnumed.125.271144.
 
 
- KUCUK NO, Coskun N, Araz M, Alan Selcuk N, et al 
 Initial Multicenter Experience with [(161)Tb]Tb-PSMA in 
[(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: 
Preliminary Results.
 J Nucl Med. 2025 Oct 3:jnumed.125.270952. doi: 10.2967/jnumed.125.270952.
 
 
- KARMANN A, Rose S, Herrmann K, Kratochwil C, et al 
 alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical 
Outcomes in Prostate Cancer.
 J Nucl Med. 2025 Oct 3:jnumed.125.270940. doi: 10.2967/jnumed.125.270940.
 
 
 J Urol
 
 
- MOSER AM, Elanjian A, Zamani A, Ginsburg KB, et al 
 The risk of clinically significant prostate cancer on subsequent biopsies in men 
with HGPIN/ASAP on an MRI-informed index biopsy.
 J Urol. 2025 Sep 29:101097JU0000000000004797. doi: 10.1097/JU.0000000000004797.
 
 
- BORGES RC, Tourinho-Barbosa RR, Dias N, de Barros Pena Ribeiro Paiva G, et al 
 Detection of Clinically Significant Prostate Cancer Using Micro-Ultrasound Versus 
MRI/Ultrasound Fusion Biopsy: A Propensity-Weighted Comparative Study.
 J Urol. 2025 Sep 26:101097JU0000000000004793. doi: 10.1097/JU.0000000000004793.
 
 
 Lancet Oncol
 
 
- SPRATT DE, Schaeffer EM 
 Revisiting prostate cancer active surveillance candidacy.
 Lancet Oncol. 2025;26:1273-1275.
 
 
 Oncology
 
 
- DI LORENZO G, Verde A, Scafuri L, Baio R, et al 
 Development and validation of the PREVES-HOR Questionnaire: a patient-reported 
measure of hormone-therapy-related quality of life in prostate-cancer patients 
undergoing androgen-deprivation therapy.
 Oncology. 2025 Sep 29:1-29. doi: 10.1159/000548317.
 
 
 Prostate
 
 
- YAZGAN SC, Bolek H, Coskunpinar M, Yekeduz E, et al 
 Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic 
Castration-Sensitive Prostate Cancer.
 Prostate. 2025 Sep 24. doi: 10.1002/pros.70062.
 
 
- QIONG L, Qingyi L, Bohong G, YouCheng H, et al 
 Influence of 5-Alpha Reductase Inhibitors on PI-RADS Scores and Prostate Cancer 
Detection: A Systematic Review and Meta-Analysis.
 Prostate. 2025 Sep 28. doi: 10.1002/pros.70066.
 
 
- FEDELE N, Wilson RJ, Doherty J, Baxi P, et al 
 Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans 
With Metastatic Castrate-Resistant Prostate Cancer.
 Prostate. 2025 Sep 28. doi: 10.1002/pros.70060.
 
 
- HAN D, Jiang C, Liu H, Ye D, et al 
 MEIS2 Modulates Oxidative Phosphorylation and ROS Generation to Affect CD8(+) T 
Cell Antitumor Immunity in Prostate Cancer.
 Prostate. 2025 Oct 1. doi: 10.1002/pros.70051.
 
 
- TANG Z, Guo P, Liu Y 
 LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via 
the p53 Signaling Pathway.
 Prostate. 2025 Oct 1. doi: 10.1002/pros.70049.
 
 
- SAKAMOTO S, Zhao X, Onozawa M, Shiota M, et al 
 Impact of Human Development Index Category on Prostate Cancer Characteristics in 
Asia.
 Prostate. 2025 Oct 1. doi: 10.1002/pros.70050.
 
 
 Urol Int
 
 
- BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al 
 Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: 
Fact or Fiction?
 Urol Int. 2025;109:501-507.
 
 
- SCHMITZ-DRAGER BJ, Schmitz-Drager BJ, Bismarck E, Ebert T, et al 
 Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a 
Real-World Setting: Results from a Prospective Cohort Study (LEAN).
 Urol Int. 2025;109:519-527.
 
 
 Urology
 
 
- HANDA N, Kaul H, Neill C, Proudfoot JA, et al 
 A novel application of Decipher testing in HoLEP specimens for risk 
stratification of incidentally detected prostate cancer.
 Urology. 2025 Oct 1:S0090-4295(25)00937-9. doi: 10.1016/j.urology.2025.
 
 
- VAFAEI E 
 Editorial Comment on "Economic Burden of Urinary Incontinence in Men with 
Prostate Cancer: Results from the Medical Expenditure Panel Survey (2016-2021)".
 Urology. 2025 Sep 26:S0090-4295(25)00911-2. doi: 10.1016/j.urology.2025.
 
 
- MAY M, Wolff I, Burger M, Brookman-May S, et al 
 Letter to the Editor on "Impact of Age, Marital Status, Smoking, and Alcohol 
Consumption on Urinary and Sexual Function in Prostate Cancer Patients Treated 
With Radical Prostatectomy: A Prospective Cohort Study".
 Urology. 2025 Sep 23:S0090-4295(25)00900-8. doi: 10.1016/j.urology.2025.
 
 
 
Free Medical Abstracts
 Privacy Policy
Privacy Policy
 Sponsors
Sponsors
 Share
Share
© Amedeo 1997-2016